Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HCV Forecast: Merck, AbbVie Next-Gen Data Not Overtaking Gilead

Executive Summary

Gilead's ASTRAL study data at AASLD represent a "shock-and-awe" campaign, setting up the company for continued HCV dominance over several competitors, Wall Street analyst asserts.


Related Content

December Approvals Forecast: FDA Decisions Will Be Fast And Frequent
Decompensated Cirrhosis May Be Another HCV Edge For Gilead; Bristol, J&J Still In Contention


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts